国药现代：阿奇霉素干混悬剂通过仿制药一致性评价

Core Viewpoint - The company has successfully passed the consistency evaluation for its Azithromycin suspension, which is expected to enhance market expansion and sales potential, although the impact on performance remains uncertain [1] Group 1: Product Development - The Azithromycin suspension is projected to achieve sales of 1.475 billion yuan in public medical institutions and urban pharmacies across China in 2024 [1] - The company has invested approximately 17.3725 million yuan in research and development [1] Group 2: Market Competition - Other companies that have also passed the consistency evaluation include Shijiazhuang Pharmaceutical Group, Eucare Pharmaceutical Co., Ltd., Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., and Hainan Puli Pharmaceutical Co., Ltd. [1]